Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.

Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.

Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.

Masood has been intimately involved in the evolution of Pharmaceuticals industry's compliance environment in challenging markets in Asia.

Charles Cain is the Deputy Chief of the Foreign Corrupt Practices Act Unit within the Securities and Exchange Commission's Division of Enforcement. He has been in the SEC's FCPA Unit since its formation and with the Division of Enforcement for seventeen years. As the Deputy Chief, his roles include oversight of the National FPCA program, coordination with the DOJ and FBI, and supervision of individual investigations. During his tenure with the SEC, he has been responsible for numerous significant FCPA matters, as well as cases across a broad range of other areas including financial fraud, insider trading, offering fraud, market manipulation, disclosure fraud, and broker dealer practices.

Gary Giampetruzzi is a partner in the Investigations and White Collar practice in the Litigation Department of Paul Hastings, based in the firm's New York office. Mr. Giampetruzzi routinely advises clients on day-to-day compliance matters, and represents corporations in high-profile federal and state investigations, including those involving federal and state False Claims Act (qui tam suits), the Foreign Corrupt Practices Act ("FCPA"), and oversees other complex civil and criminal litigation matters. While his practice cuts across numerous sectors, Mr. Giampetruzzi possesses particularly deep experience in the life sciences sector, representing many of the world's most prominent biotech, pharmaceutical, and medical device companies.

Prior to joining Paul Hastings, Mr. Giampetruzzi most recently served as Vice President, Assistant General Counsel and Head of Government Investigations at Pfizer Inc, with responsibility for government investigations across the company's multiple business units and operations globally, and Deputy Compliance Officer responsible for international compliance investigations and programs. He is highly regarded by counsel, healthcare industry insiders, and regulators for his strategic thinking and sound judgment, and brings unique experience and perspective to each representation, having himself been the client for more than a decade.

Eric Carlson advises clients operating in Asia on a range of anti-corruption laws, including the FCPA. He has deep experience leading highly sensitive anti-corruption/FCPA investigations in Asia, including investigations presenting complex legal, political, and reputational risks. He has particular experience with the pharmaceutical and medical device industries.

He also counsels clients on the corruption risks of proposed transactions, conducts anti-corruption due diligence as part of mergers, acquisitions, and joint ventures, assists companies in updating and strengthening their internal anti-corruption compliance programs. He speaks Mandarin and Cantonese and has led more than three hundred witness interviews in Chinese in 22 provinces in China, and conducted dozens of trainings in Chinese, as well as projects related to India, Indonesia, Japan, Korea, Malaysia, Singapore, Taiwan, Thailand, and Vietnam.

Eugene Chen is a partner based in Hogan Lovells' Shanghai office, and is a US-trained and experienced litigator located full-time in China to advise clients regarding advantages and liabilities of international dispute resolution. His practice focuses on cross-border disputes and investigations in the United States, China, and elsewhere in Asia.

Eugene began his career as a food and drug regulatory lawyer in Washington, DC, and has extensive litigation, compliance, and regulatory experience with the life sciences industry. For the past eight years, he has assisted clients with anti-corruption investigations and policy development in China, as well as enforcement actions by Chinese and U.S. authorities.

Hwa Soo is chair of the Health Practice Group at Kim & Chang, which is Korea's largest law firm. For over 20 years, Hwa Soo and her team have advised the large majority of multinational pharmaceutical and medical device companies that do business in Korea, in many areas and on a wide range of issues. A major focus of her practice has been compliance, including defending companies in compliance-related investigations, setting up compliance programs, and carrying out internal compliance audits. Notably she co-led the defense teams for major pharma and medical device companies in the industry-wide investigations that the Korean competition authorities carried out in the last ten years for the giving of kickbacks."

LEI LI is a partner at Sidley Austin's Beijing office, heading the Firm's anti-corruption compliance and antitrust practices in China, with a particular focus on the pharmaceutical and medical device industry. Mr. Li has advised clients on all types of investigation and compliance matters under the U.S. FCPA and Chinese anti-bribery laws. He also has advised clients on handling antitrust government investigations, and conducting internal antitrust audits and antitrust compliance programs. Mr. Li has been featured as a leading Life Sciences lawyer in China by major bar publications.

YEE CHUNG SECK leads the Firm's Healthcare, M&A and IT/C practices in Vietnam. He is highly regarded in his field -- Chambers Global, Chambers Asia, IFLR1000, and Asia Pacific Legal 500.

He has dealt with a wide range of investment projects and major M&A deals, and advised and assisted on corporate, commercial and regulatory compliance matters. This includes foreign direct investment, market access and licensing, private and public M&A, commercial contracts, competition and anti-corruption compliance, data privacy and management, over a diverse range of industries, including pharmaceuticals and healthcare, cosmetics, e-commerce, IT services, consumer products, food & beverage, manufacturing, property, and aviation.

Reuben leads the firm's Fraud Investigation & Dispute Services (FIDS) practice in ASEAN and the Forensic Technology & Discovery Services competency in Asia Pacific. As a practitioner in consulting and technology for 30 years, Reuben specializes in the application of leading digital technologies to assist clients in investigation of fraud and corruption, regulatory and corporate compliance issues and litigation support for disputes in the region. His primary areas of expertise are in fraud investigation, electronic discovery matters, misconduct investigations, IP theft investigations, and insider threats. He has worked with clients across a broad spectrum of industries giving him the advantage of introducing fresh insights on effectiveness and efficiency in evidence and case management. With the rise in digital frauds, cyber threats and massive data in corporations, he focuses on leveraging advance techniques in forensic data analytics and digital forensics to help clients mitigate financial loss risk and reputational damage. He has also been involved in large-scale implementation of fraud and anti-money laundering detection and prevention solutions for financial institutions in the region.

Stacy is a Director with Ernst & Young Singapore's Fraud Investigations & Dispute Services. She has approximately 15 years of experience in the areas of accounting, financial audit, internal controls review and investigations in the Asia region.

• Stacy's areas of specialization include investigations involving employee misconduct, corruption and fraud; litigation support and forensic due diligence projects to assist clients in address integrity and corruption risks.
• Stacy's portfolio of clients include Pharmaceutical, Airlines, Service, Retail and Manufacturing.
• Stacy is a guest speaker on fraud for Singapore universities and she regularly conducts fraud training for her clients.

Tom is currently the Head of Legal for Takeda's Greater China region and is based in Shanghai. Previously held the position as Head of Legal & Compliance for Takeda's North Asia region. Tom joined Takeda in 2011 and relocated to Shanghai from Tokyo, Japan. Prior to Takeda, Tom was in private practice as the foreign counsel for a Japanese law firm for 11 years. Tom has lived and worked in the US for twenty years before relocating to Japan. He is a US licensed attorney in the state of Pennsylvania and with the USPTO. Prior to becoming a lawyer, Tom has worked in medical research at the Albert Einstein College of Medicine in New York.

Education/Qualifications
Licensed Attorney -- State of Pennsylvania, USPTO Temple University School of Law, JD, LLM
Fujian School of Economic Management & Administration
Hamilton College

Professional experience
Andrew Frye is global Head of Business Unit Healthcare for DKSH since January 1, 2015. He joined DKSH in 2011 as Vice President, Business Development, DKSH Business Unit Healthcare.

Andrew Frye worked a large part of his career at Abbott Laboratories, building a successful track record over 20 years crossing both the pharmaceutical and nutrition industries. His track record includes a focus on market access and biologics with leadership roles in global marketing, country and regional management in North America and Asia.

Education
Andrew Frye holds a Bachelors of Science Degree in Psychobiology from the University of Southern California and a Masters Degree in Business from the Anderson School of Business at the University of California, Los Angeles.

Dave O'Shaughnessy is the VP Compliance, Clinical Operations, at Quintiles since 2012. Dave reports to Quintiles' Chief Compliance Officer, and works with senior leaders to ensure Product Development business units have effective compliance programs to mitigate business risks.

Dave spent almost 20 years at GlaxoSmithKline in a variety of R&D and Commercial roles including VP and Compliance Officer for the commercial business in Emerging Markets, Asia Pacific and Japan, and Senior Director, International Clinical Compliance in R&D, during which time he spent 6 years living in Asia. In his earlier career, Dave worked operationally in data management and subsequently training and auditing roles across clinical development activities managed in-house and at CROs.

Dave was also previously the VP, Global Compliance Strategy and Implementation at AstraZeneca Headquarters in London and managed a central, global team with responsibility for the definition and delivery of the Global Compliance Program infrastructure.

Gareth Lee is Vice President, Legal & Compliance, Asia Pacific at Cardinal Health. In this role, he heads Cardinal Health's regional legal & compliance functions in markets around the Asia Pacific.

Gareth was previously Allergan's General Counsel, Asia Pacific from 2009 till May 2015.

Gareth is a senior legal professional with 22 years experience. He started his legal career as a solicitor in the corporate & commercial practice with a leading Singapore law firm and thereafter as legal counsel with increasing scope & responsibilities in companies such as Royal Dutch Shell & Halliburton.

He has been in legal leadership positions in the pharmaceutical and medical devices industry for the past 11 years, including Baxter, Allergan and now, Cardinal Health.

Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.

Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.

Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.

Masood has been intimately involved in the evolution of Pharmaceuticals industry's compliance environment in challenging markets in Asia.

Boon is the Managing Director UCB South East Asia & Korea.

Boon began his career with the Life Sciences team of the Singapore EDB. Joining Schering-Plough in 2000, he held positions at headquarters in global marketing, the Asia-Pacific leadership team, and various positions in China including Head of Hospital Marketing, Regional General Manager and Director of Customer Solutions.

Prior to joining UCB in 2014, Boon was the Managing Director of Biogen's operations in Greater China, Korea and Southeast Asia.

Boon holds Bachelors and Masters of Science Bioengineering and is currently pursuing a PhD in Business.

Mark J. Wanda is Executive Director, Anti-Bribery/Anti-Corruption Compliance for Astellas Pharma Inc., a global multi-national pharmaceutical company with operations in over 50 countries. In his role, Mr. Wanda is responsible for developing and harmonizing global anti-bribery/anti-corruption compliance initiatives across Astellas affiliates, overseeing anti-bribery/anti-corruption investigations, and identifying and assessing anti-bribery/anti-corruption areas of risk and developing plans and processes to mitigate that risk. Mr. Wanda has been in his new role since April 2016 and has worked as in-house counsel and compliance professional in the pharmaceutical industry in the U.S. since 1992.

David Hodgson is a Partner with Deloitte & Touche LLP where he serves as the Global Leader of Enterprise Risk Services for Life Sciences and Healthcare. David's focus is on helping organizations enhance their risk management capabilities and their mechanisms for responding to high-impact risks. David specializes in the Life Sciences industry and has worked extensively with large, global companies to assist them in responding to the requirements of laws, regulations and industry codes. In this capacity he has worked extensively with the world's largest Life Sciences companies on Compliance-related issues.

Tom is currently the Head of Legal for Takeda's Greater China region and is based in Shanghai. Previously held the position as Head of Legal & Compliance for Takeda's North Asia region. Tom joined Takeda in 2011 and relocated to Shanghai from Tokyo, Japan. Prior to Takeda, Tom was in private practice as the foreign counsel for a Japanese law firm for 11 years. Tom has lived and worked in the US for twenty years before relocating to Japan. He is a US licensed attorney in the state of Pennsylvania and with the USPTO. Prior to becoming a lawyer, Tom has worked in medical research at the Albert Einstein College of Medicine in New York.

Education/Qualifications
Licensed Attorney -- State of Pennsylvania, USPTO Temple University School of Law, JD, LLM
Fujian School of Economic Management & Administration
Hamilton College

Eugene Chen is a partner based in Hogan Lovells' Shanghai office, and is a US-trained and experienced litigator located full-time in China to advise clients regarding advantages and liabilities of international dispute resolution. His practice focuses on cross-border disputes and investigations in the United States, China, and elsewhere in Asia.

Eugene began his career as a food and drug regulatory lawyer in Washington, DC, and has extensive litigation, compliance, and regulatory experience with the life sciences industry. For the past eight years, he has assisted clients with anti-corruption investigations and policy development in China, as well as enforcement actions by Chinese and U.S. authorities.

Clarissa is China Head for Global Ethics and Business Integrity department, responsible for designing an effective compliance programmer for Sanofi China to uphold the group's highest ethical standards. Clarissa has abundant people manager's experiences in the area of credit and supply chain management; distributorship and agency management with MNCs including BMS and Eli Lilly. Since 2009, Clarissa has progressed her career in the global compliance function. Since Feb. 2012, Clarissa, in her current role, has been actively engaged into Sanofi China leadership team activities.

Graduated from Shanghai University, Clarissa has also obtained a MBA degree from University of Canterbury, Christchurch, New Zealand.

Jonathan M. Shun Wah is a Senior Director - China Investigations Lead at Pfizer Inc, based in Hong Kong. Mr. Shun Wah graduated from the University of Manchester in 2004 with a degree in BA Accounting and Law and is a qualified lawyer in Hong Kong and England & Wales. Prior to joining Pfizer, he worked in the Hong Kong offices of Orrick, Herrington & Sutcliffe and Dechert LLP. Mr. Shun Wah has been involved in FCPA and other internal investigations around Asia for the last seven years.

Kristin Yang is Allergan Executive Compliance Director in AP region. She has legal background with 15 years law practicing experience with private practice focusing on merger & acquisition, and in-house in health care industry for legal and compliance.

Kristin is responsible for leading the compliance program in AP region, including the design, establishment and implementation of a robust compliance framework (setting the compliance strategy and governance model, policies & procedures, communication & training, risk assessment & monitoring, investigation and third party program etc.) and building a high integrity culture across the AP region, including China, Japan, Korea, India, ANZ, and SEA countries. Prior to joining Allergan, Kristin served as AP Compliance Director for Baxter.

Mike Zhao is currently Head of Ethics & Compliance for UCB China. Mike has over 13 years of internal control and compliance experience in MNCs across multiple industries including manufacturing, FMCG and the pharmaceutical industry, with main focus on SOX, FCPA, GAAP, Health Care Compliance, Business Ethics , Business Continuity/Crisis Mgmt, etc.

Mike oversees the country-wide compliance business as part of leadership team and has extensive experience in establishing comprehensive internal control & compliance mechanisms as well as focus on establishing enterprise risk management.

Casey is a Partner in EY's Fraud Investigation & Dispute Services (FIDS) practice, which provides compliance advisory and investigation services throughout Asia Pacific. Having worked at EY for more than 14 years and spending the last 11 years in China, Casey mainly focuses on fraud investigations and forensic accounting related services in the life sciences industry.

Casey is experienced in healthcare compliance-related reviews aimed at strengthening and optimizing clients' processes and support systems. He leverages his experience in the life sciences sector and his understanding of individual clients' operations to help clients identify key risk areas, carry out periodic assessments on those areas, and advise clients on how to proactively manage associated risks through designing and implementing compliance review programs in order to establish operational effectiveness and localization.

Aside from proactively advising life science companies on healthcare compliance programs, Casey helps clients investigate misconduct in their China operations. These investigations include improper payments, conflicts of interests and many FCPA-related bribery cases.

Casey is a Certified Fraud Examiner and speaks English, Mandarin Chinese, Cantonese and Bahasa Melayu.

Dr. Milind Antani leads the Pharma & Healthcare Practice at the multi-skilled, research-based international law firm, Nishith Desai Associates with offices in Mumbai- Nariman Point, Silicon Valley, Bangalore, Singapore, New Delhi and Mumbai – BKC, Munich and New York. He is also partner in-charge of Social Sector practice and Nanotechnology practice.

Dr. Antani represents clients on strategy, regulatory and transactional matters, corporate mergers and acquisitions, investments, intellectual property prosecution and litigation, collaborations including joint ventures and formation of new companies. He also advises clients in e-Health and tele-medicine on business strategy from legal and regulatory perspective.

He has authored and co-authored many articles, as well as a book on CRAMS and Pharma and Life science in India. He is a regular speaker and panelist at various national and international forums. He is also a visiting faculty at many institutions.

He has been included as one of the world's leading practitioners in 'Who's Who Legal' for Life Sciences 2014 and 2015 in the 'Regulatory' section as only lawyer from India.

Dr. Antani practiced as an ENT surgeon for 14 years prior to joining Nishith Desai Associates as a lawyer.

He has also successfully attended "Managing and Transforming Professional Service Firms-India" an executive training program organized by Harvard Business School.

As a co-founder of Polaris Solutions and head of the technology practice, Marc Eigner is considered one of the founding fathers of pharmaceutical commercial-compliance technology and the leading expert this field, particularly in HCP/HCO spend automation and aggregate spend systems. He is a frequent lecturer and author on these topics. Under Marc's direction, Polaris' technology practice has grown from a core team to become the largest pharmaceutical compliance-focused technology group in the industry, implementing more than one hundred spend management and aggregation systems worldwide. Thanks to his leadership, Polaris continues to innovate, enlarging the scope of its technology practice and introducing a consistent stream of new products while delivering technology strategy expertise in support of Polaris Management Partners' consulting practice.

Before joining Polaris, Marc worked for Andersen Consulting / Accenture and IBM. Marc holds a BS and MS in Computer & Systems Engineering and an MBA focused on Technology Entrepreneurship, all from Rensselaer Polytechnic Institute. Marc has participated in several executive education programs at the Harvard Business School, including 'Leading Professional Services Firms.'

Karen Eryou is currently Senior Director, Corporate Compliance, APAC for UCB. She has over 15 years of international work experience in the pharmaceutical industry including Clinical Operations, Quality Assurance, Auditing and Inspections, as well as Medical Affairs. She has focused on business practices, ethics and compliance topics for the past 5 years. Since 2011 Karen has been based in Shanghai where she was assigned to build the compliance function for UCB. Following the development and implementation of a comprehensive compliance program with the China team she now leads the compliance program for the Asia-Pacific region for UCB.

Sarah Kochling is the Managing Principal of Blossom, a strategic insights, innovation and design consultancy that supports clients to get to breakthrough consumer, market and industry insights and collaboratively transform them into meaningful impact. With over 25 years of experience in China and Asia, including management roles at Procter & Gamble China and J&J Int'l, leading innovation practices at agencies What If and Dragon Rouge and advising China startups, Sarah offers clients an optimal balance of best-practice experience and entrepreneurial savvy. Over the years she and her team have applied their skills across a broad range of consumer and professional categories for many Fortune 500 and global firms.

Maria Eugenia (Maru) Quindimil is currently APAC Ethics and Compliance lead for UCB.

Previously, Maru has been Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation advisory firm serving executives, boards, investors and advisors in diverse sectors, primarily in the Americas, Europe and Africa.

Maru, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years.

In 2015 she was internationally recognized by the World Women Congress Leadership organization for her outstanding contributions in the region with the "Women Leadership Achievement Award."

Throughout a career that has spanned 27 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors.

Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct and active contributor in AP Compliance Network. A native Argentinian, Maru has lived and worked in Latin America, Europe, the USA and Asia Pacific region.

Redentor R. Romero is the APAC Director of Compliance for Teva Pharmaceutical Investments Singapore Pte Ltd, where he is responsible for formulating and developing the Compliance Program for Teva in Asia Pacific. He is a lawyer by profession and was the Regional Legal Counsel for AstraZeneca for the Asia Area before joining Teva. Prior to joining the pharma industry, he was in legal practice, focusing on litigation, contracts and labor law.

YUET MING THAM is a partner in Sidley's Hong Kong/Singapore offices. Ms. Tham has extensive experience advising a large number of major U.S./European pharmaceutical, medical devices and healthcare services companies on compliance, clinical trials, labeling, promotional and marketing regulations, as well as on a variety of contractual and commercial matters. Prior to joining Sidley, Ms. Tham was the Head of the Asia Life Sciences Group and the Asia Head of the Regulatory, Compliance and Investigations Group at another international law firm. She was previously the Asia Pacific Regional Compliance Director for Pfizer, during which she was responsible for compliance and investigations in Japan, China, Hong Kong, Australia, Korea, India, Taiwan and several Southeast Asian countries. Ms. Tham sits on the Advisory Board of Seton Hall University's Healthcare Compliance Program for Asia. She has been acknowledged as a "Leading Lawyer" by Chambers Asia Pacific in the Life Sciences, Dispute Resolution, Anti-Corruption and Contentious Financial Regulatory categories. She has also been listed by Who's Who Legal as a "Leading Business Lawyer" in three separate categories, namely Life Sciences, Business Crime Defense and Investigations. The 2016 edition regarded her as "One of the best-informed regulatory lawyers in the region" for the life sciences sector.

Riza Faith Ybanez is Head of Legal and Compliance for Novartis Oncology, Asia-Pacific & South Africa. Prior to this role she was Legal & Compliance Head of Novartis Philippines, and Compliance Lead for Novartis Pharma Asia Cluster.

Riza holds degrees in AB English and Bachelor of Laws. She started her legal career in 2000 specializing in commercial law, IP, tax and labor. She moved to Sanofi Philippines in 2006, becoming Legal, Public Affairs and Communications Director there, before joining Novartis in 2011.

Riza was an active member of the PHAP Committees on Public Affairs (2007-2011) and Integrity & Compliance (2012-2015).

Ms. Yoo-kyung (Karen) Choi is the Compliance Lead of Pfizer Japan and Korea. She provides proactive compliance advice and oversees compliance programs in line with domestic and international anti-bribery and corruption policies and laws. Lately, she worked on various business development transactions in APAC region as a compliance counsel. Prior to joining Pfizer, she worked as a foreign legal consultant at Shin & Kim.

After receiving her LLB from Yonsei University, Ms Choi earned her LLM and JD at the University of Toronto. She is a member of the Law Society of Upper Canada.

Jooha Yang is Regional Compliance Manager of Roche Pharma Asia Pacific based in Singapore. Jooha supports and provides compliance guidance to the countries within the region as well as supports global and regional compliance initiatives. Before the regional role, she was Sr. Manager of Internal Audit & Compliance Manager in Roche Korea setting up compliance & audit framework, processes to be aligned with external regulatory environment and Roche global compliance policies. She has built up compliance expertise in healthcare industry through various experiences in GE Healthcare as well as Korean Research-based Pharmaceutical Industry Association.

Hwa Soo is chair of the Health Practice Group at Kim & Chang, which is Korea's largest law firm. For over 20 years, Hwa Soo and her team have advised the large majority of multinational pharmaceutical and medical device companies that do business in Korea, in many areas and on a wide range of issues. A major focus of her practice has been compliance, including defending companies in compliance-related investigations, setting up compliance programs, and carrying out internal compliance audits. Notably she co-led the defense teams for major pharma and medical device companies in the industry-wide investigations that the Korean competition authorities carried out in the last ten years for the giving of kickbacks."

Jasmine Karimi is the Senior Director & Counsel, heading the legal & compliance function across all Asia Pacific for Illumina Inc. (NASDAQ: ILMN), an international, rapidly growing, and the world's leading DNA sequencing company (named MIT Technology Review's "Smartest Company" in 2014, and No. 3 in 2016). Jasmine also sits on the APAC Management team and Global Legal Management at Illumina.

A seasoned in-house professional, Jasmine has over 20 years of experience, across multiple jurisdictions where she held progressively senior in-house legal roles across diverse industries (including media, manufacturing, luxury retail and currently life sciences). Prior to Illumina, she was Associate General Counsel, Asia (ex-Japan) for Coach Inc., overseeing the brand's legal and compliance work across APAC based out of Hong Kong. Preceding her in-house career, Jasmine was a corporate and litigation lawyer at major law firms in Canada and Singapore. Her areas of expertise include Corporate, Commercial, Compliance, Anti-Corruption, Intellectual Property, Technology, Employment and Data Privacy laws.

Noted for excellence in public speaking and presentations, Jasmine is a frequently invited speaker at industry and professional forums globally. She has an LL.B. (Hons) from the U.K., and an LLM specializing in IP law from Canada. She is admitted to practice law in England & Wales, Singapore, Canada, and Hong Kong. Jasmine speaks several Asian based languages with varying degrees of fluency. A firm believer in giving back, Jasmine has served on several boards and is the immediate past President of the Hong Kong Corporate Counsel Association (HKCCA). She currently sits on the SIAC Users Council.

Jasmine has been named as one of the 100 leading influential in-house lawyers in business in Asia in The Legal 500: Corporate Counsel 100 Asia 2014.

Benjamin Kwak is the Vice President, Compliance Officer and Senior Legal Counsel, Asia Pacific, for Zimmer Biomet, a U.S. medical device company. Prior to joining Zimmer Biomet, Mr. Kwak was in private practice in Washington, D.C., where he focused on white collar criminal defense, government investigations, and corporate compliance matters. He represented multinational corporations in matters involving the Foreign Corrupt Practices Act, and has conducted internal investigations and anti-corruption compliance reviews throughout Asia, Europe, and Latin America. Mr. Kwak received his B.A. in Public and International Affairs from Princeton University and his J.D. from Columbia Law School.

Alison Parkes is Vice President of Compliance at Smith & Nephew, a global medical technology business dedicated to supporting healthcare professionals.

Alison is responsible for Compliance across Asia Pacific and Emerging Markets, leading a team of professionals to ensure effective implementation and oversight of compliance controls across the region.

With a PhD in Molecular Genetics, Alison has almost 20 years' experience in the medical device industry. Prior to her current role, she was Vice President of Compliance for the Wound Management business in the United States and Europe.

Accountable for driving Abbott's Regional Ethics and Compliance Program in Asia region across its hugely diversified businesses i.e. Nutritional Products, Diabetes Care, Medical Optics, Vascular, Diagnostics, Pharmaceuticals and Molecular. One goal in mind: Nurture a robust organisation wide mindset of Triple Lenses of Responsibilities Framework -- Ethics, Economics/Finance and the Law.

An accomplished International Ethics & Compliance professional with combined 18 years of proven track record from scaling up to sustaining the Compliance Program together with Global and Regional key stakeholders. Experienced leading complex Audits and Investigations that resulted in a more robust internal controls structure and FCPA/ Anti-Bribery Anti-Corruption detective and preventive measures being put in place.

An outstanding people manager whose leadership philosophy is having a clear vision, empowering, coaching and the right intervention.

A Harvard Business School trained and well regarded industry thought leader. Rhys is currently the co-chairperson for Asia Pharmaceutical Compliance Congress, faculty member of Seton Hall University's Asia-Pacific Healthcare Compliance Program, founding member of the Asia-Pacific Healthcare Compliance Industry Group and member of the Harvard Business School Healthcare Alumni Association.

Giuseppe was the first Regional Compliance Officer in Alcon Asia & Russia. He guided the Leadership team and the Commercial Heads in establishing the Compliance framework and the function. Giuseppe was previously based in Basel where for 3 years, he was responsible for the misconduct handling process across all Novartis Divisions in Asia, Middle East, Africa and Latin America. Before Novartis, Giuseppe lived in London where he ran his own due diligence & investigation company and prior to this, worked for Kroll. Giuseppe has had extensive experience with the United States Secret Service and the Italian economic police, prior to joining the private sector.

Dr. Milind Antani leads the Pharma & Healthcare Practice at the multi-skilled, research-based international law firm, Nishith Desai Associates with offices in Mumbai- Nariman Point, Silicon Valley, Bangalore, Singapore, New Delhi and Mumbai – BKC, Munich and New York. He is also partner in-charge of Social Sector practice and Nanotechnology practice.

Dr. Antani represents clients on strategy, regulatory and transactional matters, corporate mergers and acquisitions, investments, intellectual property prosecution and litigation, collaborations including joint ventures and formation of new companies. He also advises clients in e-Health and tele-medicine on business strategy from legal and regulatory perspective.

He has authored and co-authored many articles, as well as a book on CRAMS and Pharma and Life science in India. He is a regular speaker and panelist at various national and international forums. He is also a visiting faculty at many institutions.

He has been included as one of the world's leading practitioners in 'Who's Who Legal' for Life Sciences 2014 and 2015 in the 'Regulatory' section as only lawyer from India.

Dr. Antani practiced as an ENT surgeon for 14 years prior to joining Nishith Desai Associates as a lawyer.

He has also successfully attended "Managing and Transforming Professional Service Firms-India" an executive training program organized by Harvard Business School.

Rajiv is a Director with EY's Fraud Investigation & Dispute Services. He has around 10 years of professional experience. He has an extensive experience in the area of investigations, enterprise risk management, revenue assurance program and internal audit.

He has forensic expertise in sectors such as Life Science, Real Estate, Private Equity, Retail, Insurance and IT/ITeS and has led various investigations across these sectors.

His previously experience includes expertise in the areas of fraud investigations, fraud risk management, enterprise risk management, channel reviews, supply chain management, internal audit and compliance.

He consults clients on fraud risks, investigations and framing the revenue assurance & compliance program in India and overseas.

Rajiv is author of the IIA India 1st publication "Internal Audit of Intangible Assets". He is often invited as speaker at conferences and workshops related to his sector expertise.

Sandeep Seth leads the Compliance function at Pfizer in India. He is part of the company's Executive Leadership Team and provides strategic compliance direction to Pfizer India operations. He is responsible for overall compliance strategy, framework and implementation of Compliance programs & initiatives.

Sandeep is a proficient compliance professional with over 23 years' of work experience in Compliance, Regulatory affairs, Legal and Operations with reputed MNCs. He Joined Pfizer India in February 2016.

Before joining Pfizer, his most recent role was as Compliance Director for MSD Pharmaceuticals for India Region (India, Pakistan, Sri Lanka, Bangladesh and Nepal) where he was responsible for overall Compliance strategy and culture.

Sabina is a Consultant and an adjunct professor. She currently teaches a seminar on Legal and Ethical Issues in Sustainability at the Nanyang Technological University Business School and a seminar on Sustainability Strategy at the National University of Singapore. She operates out of Singapore and New Delhi. From 2010 to 2015, Sabina was the Vice-President and Compliance Officer (Pharma) with GlaxoSmithKline, based in Singapore for all markets ex US. From 2005 to 2010, Sabina was Director Ethics & Compliance Director, Pacific Asia and Africa at Abbott Labs, based also in Singapore. Sabina is admitted to practice law in Delhi, New York and Arizona. She obtained her Bachelor of Laws (LL.B.) at Delhi University and her Masters of Laws (LL.M,) at Columbia University, New York.

Ewa Holker is the Head of Legal and Compliance (Asia Pacific) at Ferring Pharmaceuticals. She is based in Singapore and provides legal and compliance leadership and support for the APAC region. Prior to joining Ferring Pharmaceuticals, she served as Director of Legal and Compliance for Asia Pacific for Zimmer Biomet and prior to that held positions in private practice law firms as well as in-house in Perth and Sydney, Australia.

Keith Korenchuk is a partner in the FDA and Healthcare practice of Arnold & Porter, LLP in Washington D.C. He counsels and advises pharmaceutical, life sciences, medical device, biotechnology, and specialty pharmacy companies in the United States and worldwide on regulatory and compliance matters, including on the following matters:

• US and global compliance systems design, implementation, and ongoing assessment
• Regulatory matters involving healthcare professionals, including fraud and abuse, off-label promotion, False Claims Act and transparency related issues
• Global anti-bribery legislation, including the US Foreign Corrupt Practices Act, the Organization for Economic Co-operation and Development (OECD) Anti-bribery Convention, and related national implementing legislation
• Internal and government initiated investigations
• State legislation involving pharmaceutical and medical device marketing and disclosure
• Global, regional, and country specific codes of practice and conduct, including codes issues by Pharmaceutical Research and Manufacturers of America (PhRMA), AdvaMed, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and Eucomed
• Enterprise-wide risk management systems and programs
• Pharmaceutical price reporting and third party/managed markets negotiations

Carol is a well-rounded finance and compliance professional with extensive international experience matched by proven leadership qualities.

She is recognized as a top performer with business acumen and a strong, disciplined approach, backed by skills and abilities honed in a wide range of challenging appointments within the Pharmaceutical, FMCG and Chemical Industries.

She has operational experience in managing risks, change, organisational rationalisation as well as executing growth strategies.

Vivian Wu has more than ten-year experience in advising multinational companies on compliance, regulatory and other corporate issues in China. She also has in-house experience with a leading US-based healthcare multinational company. In 2014, she worked in the firm's Washington DC office on FCPA cases. Ms. Wu holds the PRC Bar Qualification Certificate (1999) and is admitted to practice in New York (2007).

Mohit is an Executive Director in Risk Consulting and leads the Life Sciences & Health Care industry in Southeast Asia. With 20 years of experience in Consulting and Life Sciences industries, he possesses in-depth expertise in enabling business growth strategies, transformations in Sales & Marketing, Finance and IT functions. He has extensive experience in delivering shared services, digital, enterprise applications and outsourcing initiatives.

Andrew has over 5 years of professional experience working in Legal and Compliance. Andrew completed his studies at the University of Technology, Sydney earning a Bachelor of Law & Medical Science.

After graduating, Andrew took up a Compliance role at Novartis Pharmaceuticals Australia and New Zealand for 3 years before accepting a role at Sanofi ANZ in 2014 as the Country Compliance Officer. Andrew is responsible for managing the overall Compliance program including implementing effective SOPs and policies, conducting internal testing/monitoring and providing strategic compliance advice to the business units.

In 2015, Andrew received his Healthcare Compliance Certification from INSEAD, one of the top business schools in Europe. Andrew highly enjoys working on Compliance projects and finds it extremely rewarding partnering with the business units.

Katsumi KOJIMA is a Corporate officer, Country Compliance officer Japan of Sanofi Group, based in Tokyo, Japan. He is a member of the Code Compliance Committee, the Japanese Pharmaceutical Manufacturers Association (JPMA) and a member of the International Federation of Pharmaceutical Manufacturers and associations (IFPMA) Code Compliance Network.

He has been working for compliance field in the pharmaceutical and medical device industries over ten (10) years. He engaged in a speaker and a panellist on compliance topics in various conferences, such as "How Do I Know It's Working? Key Performance Indicators, Metrics and More" at Asia-Pacific Economic Cooperation (Nanjing, China) in 2014, "Venues & Locations of Third Party Conferences: What is Appropriate" at Advanced Medical Technology Association and Medical Technology Association of Australia Compliance Conference (Singapore) in 2014 and "Australia and Japan transparency updates" at the Global MedTech Compliance Conference (Barcelona, Spain) in 2014.

He earned LLB from Waseda University (Tokyo, Japan) and LLM from Hitotsubashi University (Tokyo, Japan). In addition, he received certification from INSEAD Compliance Implementation Leadership 1 (Fontainebleau, France) and Seton Hall Law School Aisa-Pacific Healthcare Compliance (Singapore). Since 2010, he has served as a Visiting Lecturer at Kyoto Prefectural University of Medicine (Kyoto, Japan).

Mr. McGuire has 21 years of pharmaceutical industry experience and is a frequent speaker at international transparency conferences. He currently serves as Advisor, Global Public Policy at Eli Lilly and Company and previously served as Director, Global Transparency. In addition to US Open Payments, he played a leadership role in several working groups associated with the development and implementation of the EFPIAHCP/HCO Disclosure Code and has authored several transparency blogs. Mr. McGuire earned a Bachelor's of Business Administration in Finance at the University of Iowa and a Masters of Business Administration in Finance at DePaul University.

Kent has over 15 years' experience as a dispute resolution lawyer, concentrating on international arbitration in both London and Singapore. Kent has conducted arbitrations under leading institutional rules in most major seats, under both civil and common applicable laws.

His extensive trial experience includes high value commercial disputes across a number of sectors and jurisdictions. His final years in London were spent leading disputes between high profile Russian oligarchs, with merits hearing of claims involving some US$3bn. From Singapore he is routinely involved in disputes relating to services and infrastructure in the resources, energy and oil & gas sectors. These include construction and commodities matters and often involve South East Asia or India.

He conducts all stages of proceedings, from interim measures to advocacy at trial. He also holds full registration as a foreign lawyer to appear before the Singapore International Commercial Court.

Kent is recognised by Chambers Asia Pacific as a leading individual for Dispute Resolution: Arbitration (Singapore) in 2014 and 2015. He regularly sits as an arbitrator and is on the SIAC panel. He is a director of the Chartered Institute of Arbitrators -- Singapore branch.

Ramon leads Control Risks' forensic investigations practice for Southeast Asia, which specialises in conducting fraud- and corruption-focused corporate investigations and litigation support work across the region. Based in Singapore, Ramon has over 15 years of professional experience working with clients to investigate, review and remediate issues affecting operations across South and Southeast Asia. Ramon relocated from the UK to Asia in 2009. Prior to joining Control Risks, he practised as a commercial litigation lawyer for an international law firm in London. Ramon is a qualified Solicitor (Senior Courts of England & Wales) and holds a postgraduate degree in legal practice from the College of Law, London.

Abdul is a specialist in anti-bribery and corruption compliance with more than 20 years in the life sciences industry. Currently at KPMG leading their UK ABAC compliance practice in their Life Science practice.

Prior to joining KPMG Abdul spent 15 years with Johnson & Johnson of which 10 were in healthcare compliance where he first led the compliance organisation for LifeScan across EMEA and latterly for J&J across the Asia Pacific region.

Originally an organic chemist, post-MBA Abdul has held posts in operations management and finance across the chemical, agrichemical and healthcare industries.

Dave O'Shaughnessy is the VP Compliance, Clinical Operations, at Quintiles since 2012. Dave reports to Quintiles' Chief Compliance Officer, and works with senior leaders to ensure Product Development business units have effective compliance programs to mitigate business risks.

Dave spent almost 20 years at GlaxoSmithKline in a variety of R&D and Commercial roles including VP and Compliance Officer for the commercial business in Emerging Markets, Asia Pacific and Japan, and Senior Director, International Clinical Compliance in R&D, during which time he spent 6 years living in Asia. In his earlier career, Dave worked operationally in data management and subsequently training and auditing roles across clinical development activities managed in-house and at CROs.

Dave was also previously the VP, Global Compliance Strategy and Implementation at AstraZeneca Headquarters in London and managed a central, global team with responsibility for the definition and delivery of the Global Compliance Program infrastructure.

Sow Wei is Legal Counsel at Takeda Development Center Asia, Pte Ltd (TDC Asia), the development arm of Takeda Pharmaceuticals Company Ltd, where he provides legal and compliance support for the business as well as studies sponsored by TDC Asia. Prior to joining Takeda, Sow Wei was Senior Compliance Counsel at Allergan and before that, he held legal and compliance roles at Temasek Holdings, General Electric and SGX. Sow Wei is called to the Bar in Singapore and Malaysia, qualified as a Barrister of Lincoln's Inn and holds a LL.M from the University of Malaya.

Ms. Yoo-kyung (Karen) Choi is the Compliance Lead of Pfizer Japan and Korea. She provides proactive compliance advice and oversees compliance programs in line with domestic and international anti-bribery and corruption policies and laws. Lately, she worked on various business development transactions in APAC region as a compliance counsel. Prior to joining Pfizer, she worked as a foreign legal consultant at Shin & Kim.

After receiving her LLB from Yonsei University, Ms Choi earned her LLM and JD at the University of Toronto. She is a member of the Law Society of Upper Canada.

Michael Dusseau is a Vice President in the Global Compliance Organization of Actavis and responsible for the Global Compliance Operations function.

Michael has held senior leadership roles in the Compliance Organizations of Schering-Plough, Merck, Bayer and Actavis with broad responsibilities including the negotiation, implementation and operation of Corporate Integrity Agreements, global compliance training, global privacy program, monitoring, transparency, hotlines and compliance investigations. Michael has experience in both the Rx and Consumer segments of the business as well as in the design and implementation of compliance organizations and programs.

Michael has over 30 years of experience in the pharmaceutical industry and has held a variety of positions in sales, sales operations, information technology and compliance.

Michael holds a bachelor's degree in science from California State University, Long Beach.

ANDREW MARTIN is the Head of the Singapore Corporate & Securities Group. He specialises in M&A corporate and regulatory work, and advises on a diverse array of commercial contracts as well as all aspects of corporate counseling, corporate governance and compliance. He oversees our compliance team in Singapore, Indonesia and Malaysia, and is a member of our Global Corporate Compliance Steering Committee. In his role as an M&A practitioner he has taken the lead on developing a series of tools for the Global M&A Group to better identify and address compliance issues in M&A and JV transactions. More broadly, he is one of the lead attorneys for the Firm's compliance work in SE Asia with particular reference to corruption issues.

Maria Eugenia (Maru) Quindimil is currently APAC Ethics and Compliance lead for UCB.

Previously, Maru has been Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation advisory firm serving executives, boards, investors and advisors in diverse sectors, primarily in the Americas, Europe and Africa.

Maru, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years.

In 2015 she was internationally recognized by the World Women Congress Leadership organization for her outstanding contributions in the region with the "Women Leadership Achievement Award."

Throughout a career that has spanned 27 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors.

Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct and active contributor in AP Compliance Network. A native Argentinian, Maru has lived and worked in Latin America, Europe, the USA and Asia Pacific region.

Belinda leads the Fraud Investigation & Dispute Services practice in Singapore. She has more than 20 years of experience incorporating 12 years in leading investigations, anti-corruption and litigation support engagements. She has led enquiries relating to corruption, bribery, conflict of interests, financial statement manipulations, assets misappropriation and computation of damages in Asia Pacific and Greater China where she lived for almost 6 years. Belinda's portfolio of clients included pharmaceutical, medical devices, manufacturing and trading companies.